Abstract
Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P
| Original language | English |
|---|---|
| Pages (from-to) | 615-625 |
| Number of pages | 11 |
| Journal | Ophthalmology |
| Volume | 118 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2011 |
Fingerprint
ASJC Scopus subject areas
- Ophthalmology
Cite this
The RESTORE study : Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. / Mitchell, Paul; Bandello, Francesco; Schmidt-Erfurth, Ursula; Lang, Gabriele E.; Massin, Pascale; Schlingemann, Reinier O.; Sutter, Florian; Simader, Christian; Burian, Gabriela; Gerstner, Ortrud; Weichselberger, Andreas.
In: Ophthalmology, Vol. 118, No. 4, 04.2011, p. 615-625.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The RESTORE study
T2 - Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema
AU - Mitchell, Paul
AU - Bandello, Francesco
AU - Schmidt-Erfurth, Ursula
AU - Lang, Gabriele E.
AU - Massin, Pascale
AU - Schlingemann, Reinier O.
AU - Sutter, Florian
AU - Simader, Christian
AU - Burian, Gabriela
AU - Gerstner, Ortrud
AU - Weichselberger, Andreas
PY - 2011/4
Y1 - 2011/4
N2 - Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P
AB - Objective: To demonstrate superiority of ranibizumab 0.5 mg monotherapy or combined with laser over laser alone based on mean average change in best-corrected visual acuity (BCVA) over 12 months in diabetic macular edema (DME). Design: A 12-month, randomized, double-masked, multicenter, laser-controlled phase III study. Participants: We included 345 patients aged 73 (20/40 Snellen equivalent) with ranibizumab (22.6% and 53%, respectively) and ranibizumab + laser (22.9% and 44.9%) versus laser (8.2% and 23.6%). The mean central retinal thickness was significantly reduced from baseline with ranibizumab (-118.7 μm) and ranibizumab + laser (-128.3 μm) versus laser (-61.3 μm; both P
UR - http://www.scopus.com/inward/record.url?scp=79953311138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953311138&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2011.01.031
DO - 10.1016/j.ophtha.2011.01.031
M3 - Article
C2 - 21459215
AN - SCOPUS:79953311138
VL - 118
SP - 615
EP - 625
JO - Ophthalmology
JF - Ophthalmology
SN - 0161-6420
IS - 4
ER -